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Mitoxantrone Represses Markers of Microglial Activation and Inflammation
Cameron A. Tull
Abstract
Multiple sclerosis (MS) is a neurodegenerative disease characterized by an autoimmune
attack against myelin sheaths in the central nervous system (CNS). Resulting debilitations vary
from sensory, motor, and coordination abnormalities to visual difficulties as well as bowel,
bladder, sexual, and cognitive dysfunction (Fox, 2006). Mitoxantrone (Novantrone) is an FDAapproved drug used to treat the secondary-progressive form ofMS due to its demonstrated
immunosuppressive properties. While the mechanism of action of mitoxantrone is not yet well
understood, and is limited in its use due to cardiotoxicity, the aim of this study was to determine
the effect of mitoxantrone on microglial and astrocyte activation as a measure of the
inflammatory response. Enzyme-linked immunosorbent assays (ELISA) showed that
lipopolysaccharide (LPS) stimulates markers of activation including nitric oxide (NO),
interleukin-1-beta (IL-l b), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1)
in N9 cultured microglia, and moreover, that mitoxantrone inhibits these effects in a dosedependent manner.
Introduction
MS

The purpose of our research was to determine the specific effects of mitoxantrone on
LPS-induced activated microglial cells to elucidate the pathways through which it alters the
inflammatory response characteristic of secondary progressive multiple sclerosis.
Up to 2 million people are affected by multiple sclerosis world-wide, and approximately
300,000 to 350,000 individuals suffer from MS in the United States alone (Anderson et al., 1992).

Although women are twice as likely as men to develop MS (Fox, 2006), the disease is often
more severe in men (Voskuhl and Palaszynski, 2001). MS may be diagnosed in people between
the ages oftwenty and sixty, but it is most commonly diagnosed between the ages twenty-five to
forty years of age (Simone et al., 2000).
Multiple sclerosis is a chronic inflammatory disease of the central nervous system and is
characterized as an autoimmune reaction against the myelin sheaths that surround the nerves. In
MS the primary pathological target is myelin and it is this demyelination, oligodendrocyte loss,
and axonal degeneration that lead to the subsequent loss of neurological function (Trapp, 1999).
Patients affected by MS typically are found to have multiple lesions in cerebral white matter, and
these areas of inflammation have been seen both in autopsy specimens as well as with the use of
magnetic resonance imaging (MRI) (Fox, 2006). Lesions found in the brainstem, corpus
callosum, juxtacortical area, or adjacent to the body of the lateral ventricles, are most specific for
MS (Fox, 2006). Often these lesions are oriented perpendicularly to the lateral ventricle and are
round or ovoid (Fox, 2006). There is indication ofbreakdown of the blood-brain barrier resulting
from the development ofMS lesions. This results in the invasion ofhematogenous monocytes
and T cells into the brain parenchyma (Trapp, 1999). The immune system is implicated in active
tissue destruction by the association of inflammatory cells with new MS lesions (Trapp, 1999).
The most common form of multiple sclerosis usually strikes young adults and is termed
classical MS. Classical MS is usually marked by two distinct phases: relapsing-remitting and
secondary progressive. Initially, MS presents in relapsing-remitting form, a phase which can last
8-20 years before succeeding onto the secondary progressive stage, which is marked by
continuously progressive disabilities of the nervous system (Trapp, June 1999). With the
relapsing-remitting form ofMS, periods of sporadic neurological deficits are intermittent with
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variable periods of remission. There is no way to predict the onset of the secondary progressive
phase, and the mechanisms by which relapsing-remitting converts into secondary progressive
MS are not understood (Trapp, June 1999). Due to the fact that the vast majority of neurological
disability in patients suffering from MS is accounted for in the secondary progressive phase, it is
this phase that multiple sclerosis researchers are trying to prevent by first elucidating the
pathological processes responsible so that effective therapies might be developed.

Immune Response
Humans are protected from foreign pathogens, both bacterial and viral, by the immune
system. There are two systems of immunity - innate, or natural immunity, and acquired, also
known as adaptive or specific immunity. Essentially, what distinguishes the two types of
immunity is their respective way of recognizing microorganisms (Fearon and Locksley, 1996).
Innate immunity utilizes encoded proteins to recognize potentially harmful substances. For
example, macrophages have a receptor for lipopolysaccharide (LPS), a component of Gramnegative bacterial cell membranes, which signals the presence of infection by eliciting cytokine
synthesis. Some such cytokines are interleukin-1 (IL-l), IL-6, IL-12, and tumor necrosis factor
(TNF). The function of these cytokinesis to elicit immune response mechanisms such as
development of helper T cells and stimulation of macrophage activity (Fearon and Locksley,
1996). The innate immune response is mediated by various cells types such as neutrophils,
macrophages, and dendritic cells (Janeway et al., 1999a). Essentially the innate response is able
to react immediately and destroy pathogens upon detection, whereas the acquired immune
response requires time to plan a course of attack. Apparently, there are innate receptors present
on all cells that are specific for certain types of pathogens, and these receptors allow for the
immediacy ofthe innate immune response (Janeway, 1992).
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Acquired immunity, on the other hand, comprises lymphocytes and is very adaptable
(Fearon and Locksley, 1996). Adaptive (acquired) immunity is mediated by T -lymphocytes (T
cells) and B-lymphocytes (B cells), each of which produces T cell receptors and B cell receptors
respectively, which recognize foreign and self-antigens. These receptors are known to be part of
the immunoglobulin family of proteins. As a result of extensive recombination of the genes that
code for these receptors, each cell exhibits a structurally unique receptor. This recombination of
genes takes place during early development and also results in production ofT cells and B cells
that express specific receptors capable of recognizing a wide range ofboth foreign and selfantigens (Medzhitov and Janeway, 2000). In 1959 Burnet mapped out the theory of clonal
selectivity, which still serves to explain the notion of autoimmunity - how individuals are
protected from self-tissue attack by the immune system. According to this theory, at the time of
T cell differentiation in the thymus, autoreactive T cells are deleted. This process results in a
wide range ofT cells and B cells that recognize foreign but not self-antigens in the mature
individual (Burnet, 1970). Furthermore, aT cell orB cell specific for an antigen that becomes
activated by that antigen will undergo proliferation in order to produce sufficient numbers of
cells necessary for an adequate response. This process is referred to as clonal expansion and
results in the output of effector cells that respond directly against the pathogen that stimulated
both their production and the production of memory cells. Memory cells allow for a more rapid
response in the event of subsequent exposure. Memory cells are lymphocytes, and their
production serves as the foundation for both active and passive immunity. Active immunity
occurs in response to infection of pathogens whereas passive immunity occurs in response to
antigens from inactivated pathogens following vaccination (Picker and Siegelman, 1999).
Although it is clear that acquired immunity provides the body with powerful long-term immunity
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and is highly antigen specific, acquired immunity is ineffective until memory and effector
lymphocytes are produced. This process can take up to two weeks, making innate immunity vital
in that it holds the invading pathogen in check, thus giving the acquired immune response time to
gather forces for attack (Janeway et al., 1999b, c).

Etiology ofMS
MS is considered an autoimmune disease because, in individuals suffering from MS, the
immune system attacks self-antigens in the body's CNS. It is this self-attack that causes
neuropathology. In an effort to explain the development of autoinununity, there are two primary
theories that will be discussed here: the molecular mimicry theory and the clonal selection theory
(Rouse and Deshpande, 2002; Burnet, 1959). Molecular mimicry is the idea that an immune
response can be elicited by viral antigens that maintain sufficient molecular similarity to selfantigens. The reason that autoimmune diseases do not develop under normal circumstances is
that during development, lymphocytes that have high affinity receptors for self antigens are
deactivated (Rouse and Deshpande, 2002). Although autoreactive lymphocytes are still present,
they are not activated in normal healthy individuals. Also, it has been shown that lymphocyte
receptors on T cells might not be as specific as once thought. In effect, several epitopes might
have the capability of reacting with a single receptor due to this degeneration ofT cell
recognition specificity. An epitope is the surface portion of an antigen. It is capable of both
eliciting an immune response and of combining with the antibody produced to counter that
response (Houghton Mifflin, 2002) . In essence, once an antigen has exacted a response, the
expansion ofT cell clones could react with other epitopes not excluding self proteins presented
by self major histocompatibility complex (MHC) (Rouse and Deshpande, 2002). Although the

'
specific cause ofMS is not known, many viruses could contribute its pathogenesis. This is
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considered a possibility by some based on observations that relapses of symptoms in those
suffering from MS are often preceded by microbial infections (Martinet al., 2001). In short, viral
infections could initiate and cause expression of autoimmune disease when they result in a crossreaction between host autoreactive T cells and the foreign agents (Rouse and Deshpande, 2002).
The invading virus activates myelin-specific T cells by molecular mimicry (Martinet al., 2001).
As mentioned earlier, lymphocytes that have high-affinity receptors for self antigens are
eliminated during development. This notion is the clonal selection theory of acquired immunity
(Burnet, 1959). If, as the clonal selection theory (CST) holds, all antigen receptors that might
recognize self-antigens must be purged, then autoimmunity is technically not possible.
Regardless, autoimmune diseases do occur, often in the aftermath of infection. Keeping true to
the CST, receptors are deleted that recognize self-antigens; however, an infectious agent is
capable of disregarding the deletions and instead presenting epitopes that "mimic" host epitopes.
So, while the CST keeps the immune system from stimulating self-recognition, "pseudo -self
recognition" can occur. Accordingly, the clonal selection and molecular mimicry theories can
coexist (Cohen, 2000).
There are several contributing factors to the development ofMS and other autoimmune
diseases (AID) such as environment, genetics, and hormones. It is thought that environmental
factors play a role in triggering autoimmune disease even in individuals genetically predisposed
to AID. According to Davidson and Diamond (200 1), the importance of environmental triggers
has become evident through studies of populations that are genetically similar, but because they
live in different locations, are exposed to differing environmental conditions. Specific gene
mutations have been shown to correlate to several autoimmune diseases. An example is found in
comparing the rate of AID in monozygotic and dizygotic twins (Davidson and Diamond, 2001).
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Specifically with MS, monozygotic twins have much higher concordance of the disease. So too,
the disease is much more common in biologically related family members than in adopted family
members with no biological relation (Noseworthy, 1999). It should be noted that while there are
some autoimmune diseases that result from single gene mutations, the majority are associated
with multiple gene mutations (Wucherpfennig, 2001).
Furthermore, hormonal control is thought to contribute to AID development. Multiple
sclerosis occurs more often in females than males; in fact, this holds true for many other
autoimmune diseases. While the mechanisms responsible for this gender difference are unclear,
several studies have suggested that the disproportion is due to the influence of sex steroids on
onset and exacerbations ofMS (Drew and Chavis, 2000). It has been observed that steroidal
changes that occur during gestation affect symptoms of MS. In short, during the third trimester
ofpregnancy there often is a general remission of symptoms while the postpartum period is
marked by exacerbations (Confavreux et al., 1998).
Since the 1970s, mitoxantrone has been used to treat various non-lymphocyte leukemias
as well as both prostate and breast cancer (Neuhaus et al., 2006). However, in October of2000,
the FDA approved the agent for treatment of severe forms ofrelapsing-remitting MS and
secondary progressive MS (Koeller and Eble, 1988; Jain, 2000). Because MS is thought to be an
autoimmune disease, immunosuppressants such as mitoxantrone might slow the progression of
demyelination. Mitoxantrone is a powerful immunosuppressive drug that targets proliferating
immune cells such as T and B lymphocytes and macrophages (Neuhaus et al., 2006). Chemically,
mitoxantrone, 1,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl]-amino]-ethyl]-amino ]-anthraquinone
dihydrochloride, C 22 H 28N406 • 2HC1, is a synthetic anthracenedione derivative with a molecular
mass of 517.4 Da (Neuhaus et al., 2006) (Figure 1). Mitoxantrone is a topoisomerase II inhibitor
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(Koeller and Eble, 1988), and this interaction results in single- and double- strand breaks in DNA
by ligating the DNA at specific sites in the course of synthesis (Neuhaus et al., 2006). What
occurs is an arrest at an important step in synthesis and is believed to be caused by mitoxantrone
stabilizing the cleavable complex oftopoisomerase II (Osheroff et al., 1994). This halt in cell
cycle progression leads to an accumulation of cells in the G2 phase, and this activity of
mitoxantrone has been demonstrated in human fibroblast cell lines (Fox and Smith, 1990).

HO

0

H-N-CH1 -CH1 -NH-CH.1 ·CH,-OH

• 2HCI

Figure 1. Structure of mitoxantrone.

Pharmacokinetically, mitoxantrone is 78% bound to plasma proteins, has a plasma half
life somewhere between 25 and 215 hours, and is eliminated by both the liver and kidneys.
However, from the liver and kidneys collectively, less than 35% was recovered within five days
after administration. More so, the agent has been shown to remain in cancer patients for close to
nine months. Unfortunately, studies on the ability of mitoxantrone to penetrate the blood-brain
barrier have shown contradiction (Neuhaus et al., 2006). Extent of treatment is cumulative dose
of 140 mg/m2, or a time period of2 to 3 years (Neuhaus et al., 2005). These restrictions on
mitoxantrone treatment time and dosage are due to the drug' s association with cardiotoxicity,
specifically congestive heart failure. The mechanisms by which mitoxantrone modulates multiple
sclerosis have not been elucidated, and it is our hope that clarification of these pathways will
lead to safer, more effective therapies for individuals living with this disease.
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Role of microglia in MS
Central to the pathology ofMS is the MS lesion and subsequent demyelination. Myelin
destruction occurs amidst an inflammatory reaction consistent ofT cells, B cells, macrophages,
and widespread microglial/macrophage activation (Bruck, 2005). Therefore, not only do
autoreactive T cells play a role in MS pathology, but activated microglia are also thought to take
part. Microglia are the primary cellular component of the endogenous CNS
immune/inflammatory defense system (Ransohoff, 1999). These cells are found near endothelial
cells, sporadically in the parenchyma, and in the perivenular regions (Sriram and Rodriguez,
1997). Characteristic of microglia is their fast response to inflammation, injury, infection, and
neurodegeneration (Benveniste, 1997). In order forT cells to recognize antigens, these antigens
must be presented and this process is carried out by antigen presenting cells (APCs). Microglial
ce11s can function as antigen-presenting cells and produce and respond to a wide variety of
cytokines. However, it has been established that microglia in and surrounding MS lesions
become activated, and upon doing so, undergo a morphological change into macrophages
(Ransohoff, 1999). They can impair blood-brain barrier (BBB) function, mediate phagocytic
events, and damage oligodendrocytes, the cells that produce myelin in the central nervous system
(Benveniste, 1997). The MS inflammatory reaction is linked to an up-regulation of various
cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a), and chemokines
such as mouse monocyte chemotactic protein- I (MCP-1 ). Cytokines are proteins that are made
by cells that affect the behavior of other cells. Cytokines made by lymphocytes are often referred
to as interleukins (IL) or lyrnphokines (Janeway and Travers, 1994). Chemokines are simply
small cytokines and are involved in migration and activation of cells, specifically phagocytic
cells and lymphocytes (Janeway and Travers, 1994). The activated microglia produce these
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Figure 2 represents a schematic model ofCNS demyelination As seen, the process is
initiated by microglial activating factors. Activated microglia secrete cytokines, organic
molecules, excitatory amino acids, and chemokines that sustain inflammation and demyelination.
(HSP =heat shock protein; EAA =excitatory amino acid.)
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From: Sriram: Neurology, Volume 48(2).February 1997.464-470
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Microglia: effects on T cell phenotype
In order to evaluate the effects of microglia on T ceU phenotype, specific mouse strains
are induced with experimental autoimmune encephalomyelitis (EAE). EAE is a
neurodegenerative disease specifically occurring in rodents and serves as an animal model for
MS (Benveniste, 1997). EAE is induced in rodents by the adoptive transfer ofCD4+ T cells that
are specific for myelin antigens (Drew, 2005). T-helper 1 (Thl) and T-helper 2 (Th2) cells are
the two types ofCD4+ T cells. Each type produces different types of cytokines. Thl cells
produce and release IL-l, IL-2, TNF-a, lymphotoxin (LT), and IFN-y, whereas Th2 ceUs
produce and release IL-4, IL-10, IFN-~, and TGF-

~.which

appear to be linked to disease

remission (Benveniste, 1997). Secondly, Thl cell response is coupled with cell-mediated
immunity and is responsible for delayed-type hypersensitivity, while Th2 cell reaction is
associated with humoral immunity, stimulation of allergic response mechanisms, and increased
production of antibodies (Drew, 2005).

Microglia: antigen presentation
Lymphocytes are the primary components of the immune response, but they rely heavily
on phagocytic cells of the monocyte-macrophage system for presentation of antigen toT
lymphocytes. In the case of autoimmune disease, these APCs present self-peptides to T cells
resulting in pathology. This process is referred to as a failure of self-tolerance (Young and Heath,
2000). It is important to note that both the innate component, as well as the acquired component
ofthe immune system, play a role in antigen presentation. Cells derived from monocytes, such as
macrophages and microglia, are representative of the innate component and are collectively
referred to as "professional APC." Equally, cells of the adaptive component are CD4+ T-helper
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cells, CD8+ T -cells, and B cells. This class is referred to as major histocompatibility complex
(MHC) (Drew, 2005).

Materials
Mitoxantrone
Mitoxantrone, 1,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl]-amino ]-ethyl]-amino ]anthraquinone dihydrochloride, (C22H2sN40 6 • 2HC1) was prepared in dimethyl sulfoxide
(DMSO) to a final stock concentration of20 mM (Drew).

Lipopolysaccharide (LPS)
Lipopolysaccharide (LPS) was prepared in sterile phosphate buffer saline (PBS) to a
stock concentration of 500flg/ml.

Methods
Cell Culture
The N9 microglial cell line was derived from mouse cerebrum and immortalized by
transfection with the v-myc oncogene (Righi et al., 1989; Corradin et al., 1993). N9 cells were
cultured at 37° C and 5.0% C02 in Eagle's minimum essential medium with Earle's salts
(Mediatech Ce11gro, Herndon, VA) containing a final concentration of 10% fetal bovine serum
(FBS) and 1.38mM L-glutamine (Sigma, St. Louis, MO). The N9 cell line was provided as a gift
to Lori Hensley, Ph.D. (Ouachita Baptist University, Arkadelphia, AR, USA) by Paul Drew,
Ph.D. (University of Arkansas for Medical Sciences, Little Rock, AR, USA).
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MTT Assay
Cell viability was measured with an MTT (3-(4,5-dimethylthiazone-2yl)-2,5diphenyltetrazolium bromide) assay, which measures mitochondrial activity. MTT solution was
prepared by diluting MTT 1:50 with culture medium. Cell culture media was removed and
replaced with lml MTT solution and incubated at 37° C for one hour. MTT solution was
removed and cells were lysed by adding 1ml DMSO/well. Plates were rocked for 30 minutes and
read on a plate reader at 570nm.

Nitrite Assay
For 1OOml Gries reagent, 1g of sulfanilamide, 0.1 g N( 1-naphthyl)ethylenediamine
(C12Hl4N2 2HC1), 2.5rnl phosphoric acid, and 97.5ml H 20 were added together.
Cells were plated in a 6-well plate at 6.4 x I 05 cells/well and incubated for 24 hours before
treatment with mitoxantrone. Cells were then incubated 4 hours before inducing activation ofN9
microglial cells with LPS. Media were harvested from wells after 24 hours, and 501!1 of each
sample was added to a 96-well plate with 501!1 Gries reagent and read on a plate reader at 550nm.

IL-6 ELISA Assay
IL-6 production by microglia was determined according to manufacturer' s
recommendations (BD Biosciences-PharMingen, San Diego, CA). For analysis ofiL-6,
microwells were coated with 100111 per well of Capture Antibody diluted in Coating Buffer. The
plate was sealed and incubated overnight at 4° C. The wells were aspirated and washed 3 times
with 3001!1/well ofwash buffer. The plates were then blocked with 200111/well of Assay Diluent.
The plate was then incubated at room temperature for 1 hour. The wells were again aspirated and
washed 3 times with 3001!1/well of wash buffer. Standard and sample dilutions in Assay Diluent
were prepared. 100111 of each standard, sample, and control were pipetted into appropriate wells.
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The plate was sealed and incubated for 2 hours at room temperature. The wells were again
aspirated and washed, but with a total of 5 washes. I OOf.!l of Working Detector (Detection
Antibody+ SAv-HRP reagent) were added to each well, and the plate was sealed and incubated
for 1 hour at room temperature. The wells were then washed again, but with 7 total washes.
I OOf.!l of Substrate Solution were then added to each well. Next, the plate was left to incubate
unsealed in the dark for 30 minutes at room temperature. 50f.!l of Stop Solution were then added
to each well. Finally, the absorbance was read at 450nm within 30 minutes of stopping reaction.
IL- 1p ELISA Assay

IL-l p production by microglia was determined according to manufacturer's
recommendations (BD Biosciences-PharMingen, San Diego, CA). For analysis ofiL-lp,
microwells were coated with lOOf.!l per well of Capture Antibody diluted in Coating Buffer. The
plate was sealed and incubated overnight at 4 o C. The wells were aspirated and washed 3 times
with 300f.!llwell ofwash buffer. The plates were then blocked with 200f.!l/well of Assay Diluent.
The plate was then incubated at room temperature for 1 hour. The wells were again aspirated and
washed 3 times with 300f.!Vwell of wash buffer. Standard and sample dilutions in Assay Diluent
were prepared.l OOf.!l of each standard, sample, and control were pipetted into appropriate wells.
The plate was sealed and incubated for 2 hours at room temperature. The wells were again
aspirated and washed, but with a total of 5 washes. IOOf.!l of Detection Antibody diluted in Assay
Diluent were added to each well. The plate was then sealed and incubated at room temperature
for 1 hour. The wells were again washed, with a total of five washes. Next, I OOf.!l of Enzyme
Reagent diluted in Assay Diluent were added to each well. The plate was sealed and incubated
for 30 minutes at room temperature. The wells were then washed with a total of7 washes,
followed by the addition of IOOf.!l of Substrate Solution to each well. The plate was then
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incubated without plate sealer for 30 minutes at room temperature in the dark. 50J.!.I of Stop
Solution was then added to each well. The absorbance was read at 450nm within 30 minutes of
stopping reaction.

MCP- 1 ELISA Assay
MCP-1 production by microglia was determined according to manufacturer's
recommendations (BD Biosciences-PharMingen, San Diego, CA). For analysis ofMCP-1,
microwells were coated with lOOJ.!.I per well of Capture Antibody diluted in Coating Buffer. The
plate was sealed and incubated overnight at 4° C. The wells were aspirated and washed 3 times
with 300j.l.llwell ofwash buffer. The plates were then blocked with 200J.!.IIwell of Assay Diluent.
The plate was then incubated at room temperature for I hour. The wells were again aspirated and
washed 3 times with 300J.!.IIwell ofwash buffer. Standard and sample dilutions in Assay Diluent
were prepared.) OOJ.!.I of each standard, sample, and control were pipetted into appropriate wells.
The plate was sealed and incubated for 2 hours at room temperature. The wells were again
aspirated and washed but with a total of 5 washes. I OOJ.!.I of Working Detector were added to
each well, and the plate was sealed and incubated for 1 hour at room temperature. The wells
were then washed again but with 7 total washes. I OOJ.!.I of Substrate Solution were then added to
each well. Following this step, the plate was left to incubate unsealed in the dark for 30 minutes
at room temperature. 50J.!.I of Stop Solution were then added to each well. Finally, the absorbance
was read at 450nm within 30 minutes of stopping the reaction.
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Results
The Effect of Mitoxantrone on the viability of N9 microglial cells induced by LPS
Cell

viability

was

measured

with

an

MTT

(3-(4,5-dimethylthiazone-2yl)-2,5-

diphenyltetrazolium bromide) assay, which measures mitochondrial activity. Cells were pretreated for 4 hours with the indicated concentrations of the chemotherapy agent mitoxantrone.
LPS was added as indicated and 24h later cell viability was determined. If the cells were living,
mitochondria would convert the chemical and show purple color. If cells were dead, there would
be no purple color. Our results indicated that mitoxantrone does not affect the viability of N9
microglial cells induced by LPS (Figure 3).

The Effects of Mitoxantrone on Nitrite Production in N9 Microglia
Nitrite (NO), in large enough amounts, can be toxic to myelin producing
oligodendrocytes. This assay was carried out to specifically determine the effect of mitoxantrone
on NO production in N9 microglia cells. Cells were pre-treated for 4 hours with the indicated
concentrations ofthe chemotherapy agent mitoxantrone. LPS was added as indicated, and 24h
later the concentration of nitrite in the culture medium was determined. Our results indicate that
mitoxantrone significantly inhibits LPS-induced production of nitrite in N9 microglial cells, as
hypothesized (Figure 4). An MTT assay was performed to determine cell viability, and it was
revealed that mitoxantrone does not affect N9 microglial viability. From these results, we can
thus conclude that the LPS-induced inhibition ofNO production by mitoxantrone is not a result
of the compound's effects on viability.
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The Effects of Mitoxantrone on IL-6 Production in N9 Microglia
IL-6 is a cytokine produced by macrophages and has long-range effects that aid in host
defense. IL-6 is an endogenous pyrogen, meaning it arises from an endogenous source and
causes fever, which contributes to fighting infection. T cells and B cells augment antigen
processing and thus increase the adaptive immune response (Janeway and Travers, 1994). In the
event of an autoimmune disease, T cells attack self tissue "thinking" it is foreign.
Cells were pre-treated for 4 hours with the indicated concentrations ofthe chemotherapy
agent mitoxantrone. LPS was added at a final concentration of .0626mg/ml as indicated and 24h
later the concentration ofiL-6 in the culture medium was determined. It was shown that
mitoxantrone inhibited the LPS-induced production ofiL-6 in N9 microglial cells. Cell viability
was determined using an MTT assay, and it was shown that mitoxantrone does not reduce
microglial cell viability when compared to LPS-treated cells. (See figure 5)
The Effects of Mitoxantrone on IL-lP Production in N9 Microglia
Although the procedure to determine

IL-l~

(interleukin-1 ~) production by microglia was

carried out according to the manufacturer's recommendations (BD Biosciences-PharMingen, San
Diego, CA), the concentration ofLPS was not sufficient to elicit LPS stimulation in the
microglia cells. The concentration was adjusted in step-wise fashion, but even at a four-fold
increase in LPS it was still not adequate to stimulate cytokine production.
The Effects of Mitoxantrone on MCP-1 production in N9 Microglia
Although the procedure to determine MCP-1 (mouse monocyte chemotactic protein- I)
production by microglia was carried out according to the manufacturer's recommendations (BD
Biosciences-PharMingen, San Diego, CA), the resulting data were outside the linear range ofthe
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plate reader. Therefore, the medium was diluted to 1: 250, but results still remained outside
linear range.

LPS Treatment
.None
•

.0626J!g/ml

•

.2504Jlg/ml

Figure 3. Mitoxantrone does not affect the viability of N9 microglial cells induced by LPS.
Cells were pre-treated for 4 hours with the indicated concentrations of the chemotherapy agent
mitoxantrone. LPS was added as indicated and 24h later cell viability was determined. Values
represent the average for triplicate cultures and standard deviations are indicated.
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Figure 4. Mitoxantrone inhibits LPS induction of nitrite in N9 microglia cells.
Cells were pre-treated for 4 hours with the indicated concentrations ofthe chemotherapy agent
mitoxantrone. LPS was added as indicated and 24h later the concentration of nitrite in the
culture medium was determined.
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Figure 5. Mitoxantrone in bib its LPS induction of IL-6 in N9 microglia cells.
Cells were pre-treated for 4 hours with the indicated concentrations of the chemotherapy agent
mitoxantrone. LPS was added at a final concentration of .0626mg/ml as indicated and 24h later
the concentration ofiL-6 in the culture medium was determined. Values represent the average
for triplicate cultures and standard deviations are indicated.
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Discussion
In October of2000, the FDA approved mitoxantrone for treatment of severe forms of
relapsing-remitting MS and secondary progressive MS (Koeller and Eble, 1988; Jain, 2000).
However, mitoxantrone has been used to treat various non-lymphocyte leukemias as well as
prostate and breast cancer since the 1970s, (Neuhaus et al., 2006). MS is thought to be an
autoimmune disease, and for this reason, immunosuppressants such as mitoxantrone might slow
the progression of demyelination. Mitoxantrone is a powerful immunosuppressive drug that
targets proliferating immune cells such as T and B lymphocytes and macrophages (Neuhaus et
al., 2006).
Mitoxantrone has been shown to repress microglial activation as well as impede
proliferation of lymphocytes induced by antigen. The pathway by which mitoxantrone might
repress activation of microglia in autoimmune disease is mediated by a type of feedback loop
between cytokines and T-helper cells (Drew, 2005). Activated microglia/macrophages present
antigen via MHC molecules to CD4+T-helper cells. Subsequently, said T-cells become activated
which then produce and release cytokines which in tum exacerbates the activation of the
microglia/macrophages. These molecules, such as NO, TNF-a, and interleukins, released from
activated microglia, can have an adverse effect on oligodendrocytes. Damaged oligodendrocytes
result in demyelination of nerves which lead to the severe symptoms MS (Benveniste, 1997).
Our results indicate that mitoxantrone significantly inhibits LPS-induced production of
nitrite in N9 microglial cells, as hypothesized. An MTT assay was performed to determine cell
viability, and it was revealed that mitoxantrone does not affect N9 microglial viability. From
these results, we can conclude that the LPS-induced inhibition ofNO production by
mitoxantrone is not a result of the compound's effects on viability. By reducing NO with
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mitoxantrone, neurodegeneration could be significantly curtailed, implying an alleviation ofMS
symptoms and heightened viability of myelin-producing oligodendrocytes. Moreover,
mitoxantrone has also been shown through our studies to inhibit interleukin-6 (IL-6), an
inflammatory cytokine in microglial cells. As evidenced in Figure 4, IL-6 was inhibited in
microglial cells by mitoxantrone. The implication is that cytotoxicity of o ligodendrocytes is
decreased and thus neurodegeneration moderated.
Although the procedure to determine IL-l p production by microglia was carried out
according to the manufacturer' s recommendations (BD Biosciences-PharMingen, San Diego,
CA), the concentration ofLPS was not sufficient to elicit LPS stimulation in the microglia cells.
The concentration was adjusted in step-wise fashion, even at a four-fold increase in LPS, but it
was still not adequate to stimulate cytokine production. In the future this assay will continue to
be run at varied concentrations ofLPS in effort to determine the concentration at which LPS
stimulation occurs. Similarly, although the procedure to determine MCP-1 (mouse monocyte
chemotactic protein- I) production by microglia was carried out according to the manufacturer's
recommendations (BD Biosciences-PharMingen, San Diego, CA), the resulting data were
outside the linear range of the plate reader. Therefore, the medium was diluted to
1: 250, but results still remained outside linear range. This assay will continue to be run at varied
dilutions of media samples until samples fall into the linear range.
In conclusion, mitoxantrone was seen to maintain an inhibitory effect on LPS-induced N9
microglial cell activation. Specifically, these effects include the marked decrease of
proinflammatory molecules such as NO and IL-6. As it has been observed that these molecules
mediate pathogenesis of the neurodegenerative disease multiple sclerosis, the repression of
activated microglia could potentially lead to an increase in oligodendrocyte viability and, thus,
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lessened severity of multiple sclerosis. Our lab plans to investigate a new agent, ajulemic acid,
using the same experiments described here. Our hope is that it will modulate microglial
activation in a similar manner and may one day provide a safe and more effective treatment
option for those living with MS.
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